Shomporko Desk:-Chinese authorities have granted the first invention patent to a domestically developed COVID-19 vaccine candidate, which experts said demonstrates the vaccine’s originality and creativity and would enhance the international market’s trust in Chinese-developed COVID-19 vaccines.
The vaccine, a recombinant adenovirus vaccine named Ad5-nCoV, is co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc., one of the vaccine candidate’s co-developers, and a team led by Chinese military infectious disease expert Chen Wei.
According to a document published on China’s National Intellectual Property Administration website, the vaccine can be mass-produced in a short time in the event of an outbreak.
![](https://shomporko.ca/english/wp-content/uploads/2020/04/Economy-Canada-1-1.jpg)
The grant of the patent further confirmed the vaccine’s efficacy and safety and convincingly demonstrated the ownership of its intellectual property rights (IPR), CanSino said in a statement on Sunday.
Tao Lina, a Shanghai-based vaccine expert, said the patent grant would probably facilitate the marketing process. An officially granted patent would also enhance market confidence in Chinese-developed COVID-19 vaccines, especially in the international market, added Tao.
Photo credit: Reuters
News source: CGTN